GlassScriptPhysician profile
Donald D Newman
NPI 1225131329
$7,843.82
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,306 · 2020: $1,982 · 2021: $2,315 · 2022: $1,130 · 2023: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,468.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $901.64 | 2019-2022 | |
| Amgen INC. | $758.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $699.94 | 2019-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $686.22 | 2019-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $403.32 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $394.34 | 2019-2022 | |
| Astellas Pharma US INC | $393.21 | 2019-2022 | |
| Pfizer INC. | $339.43 | 2019-2022 | |
| Abbvie INC. | $212.22 | 2021-2022 | |
| Lilly USA, LLC | $184.60 | 2019-2023 | Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $179.24 | 2019-2022 | |
| Abbott Laboratories | $167.37 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $131.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.77 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86.78 | 2019-2023 | Shingrix |
| Teva Pharmaceuticals USA, INC. | $84.54 | 2019-2021 | |
| Esperion Therapeutics, INC. | $81.43 | 2020-2021 | |
| Allergan, INC. | $78.98 | 2020 | |
| Amarin Pharma, INC. | $78.31 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $61.49 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.10 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.47 | 2021 | |
| Dexcom, INC. | $31.97 | 2021-2022 | |
| Mannkind Corporation | $31.35 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.03 | 2023 | Abilify Maintena, Rexulti |
| Sanofi Pasteur INC. | $26.79 | 2020 | |
| Eisai INC. | $23.43 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.97 | 2022 | |
| Corcept Therapeutics | $19.88 | 2019 | |
| Optinose US, INC. | $19.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.76 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.01 | 2023 | Quviviq |
| Valeritas, INC. | $16.34 | 2019 | |
| Almatica Pharma LLC | $14.82 | 2022 | |
| Currax Pharmaceuticals LLC | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.